Publication Date:
2015
abstract:
Lenalidomide is an immunomodulatory drug (IMiD) used principally in the treatment of multiple myeloma (MM), myelodysplastic syndromes (MS) and amyloidosis. Adverse reactions related to lenalidomide include myelosuppression (mainly neutropenia but also thrombocytopenia), gastrointestinal problems, skin eruption, atrial fibrillation and asthenia, decreased peripheral blood stem cell yield during stem cell collection, venous thromboembolism, and secondary malignances. In this review we focused our attention on the cutaneous adverse reactions to lenalidomide.
Iris type:
14.a.1 Articolo su rivista
Keywords:
Adverse cutaneous reactions; Amyloidosis; Erythema multiforme; Immunomodulatory drugs; Lenalidomide; Multiple myeloma; Myelodisplastic syndromes; Stevens–Johnson syndrome; Toxic epidermal necrolysis
List of contributors:
Imbesi S;Allegra A;Calapai G;Musolino C;Gangemi S
Published in: